Pfizer Obtains Approval For Macular Degeneration Drug Macugen In Japan
This article was originally published in PharmAsia News
Executive Summary
Pfizer Japan announced it obtained approval for age-related macular degeneration drug Macugen (pegaptanib) intravitreal injection kit 0.3mg. A treatment for wet AMD, Macugen was approved by U.S. FDA in December 2004. In Japan, the drug was designated as an orphan drug in July 2004 and Pfizer applied for approval in March 2007. The risk of AMD increases as a person ages and in Japan and Europe, the number of AMD patients is estimated to increase. (Click here for more - Japanese language
You may also be interested in...
Entries Begin To Roll In For 2024 Industry Awards
Entries have now begun rolling in for the Global Generics & Biosimilars Awards, which returns to Milan this October, Free to enter and attend, the ceremony recognizes the top achievements across the generics, biosimilars and value added medicines industries.
‘I Would Love To Have All The Biologic Assets’ – Formycon’s Glombitza Sets Out Portfolio Approach
In the second part of an exclusive interview, Formycon CEO Stefan Glombitza talks to Generics Bulletin about key regulatory developments in Europe and the US, the firm’s portfolio selection strategy, and upcoming milestones on the horizon.
First Off The Blocks, Fresenius Launches US Tocilizumab Biosimilar
Fresenius Kabi has kicked off competition to Genentech’s Actemra in the US, launching its Tyenne biosimilar version of tocilizumab.